NYXH Nyxoah

Nyxoah to Release Third Quarter Financial Results on November 8, 2022

Nyxoah to Release Third Quarter Financial Results on November 8, 2022

Nyxoah to Release Third Quarter Financial Results on November 8, 2022

Mont-Saint-Guibert, Belgium – October 18, 2022, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will release financial results for the third quarter of 2022 on Tuesday, November 8, 2022, after market close. Company management will host a conference call to discuss financial results that day beginning at 10:30pm CET / 4:30pm ET.

Investors interested in listening to the conference call may do so by registering for a unique personal PIN at the following link: . A live and archived webcast of the event will be available on the Company’s investor relations website at .

About Nyxoah

Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoah’s lead solution is the Genio® system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest. 

Following the successful completion of the BLAST OSA study, the Genio® system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company is currently conducting the DREAM IDE pivotal study for FDA and US commercialization approval.

For more information, please visit .

Caution – CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.

Contacts:

Nyxoah

Loic Moreau, Chief Financial Officer



0

Jeremy Feffer, VP IR and Corporate Communications



 

Attachment



EN
18/10/2022

Underlying

NYXHNyxoah

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Nyxoah

 PRESS RELEASE
Free
NYXH NYXOAH

Invitation to attend the extraordinary shareholders’ meeting of the Co...

Invitation to attend the extraordinary shareholders’ meeting of the Company to be held on July 2, 2025 REGULATED INFORMATIONJune 13, 2025, 7:00am CET / 1:00am ET NYXOAH SA(Euronext Brussels/Nasdaq: NYXH) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium(hereinafter the “Company”) Invitation to attend the extraordinary shareholders’ meeting of the Company to be held on July 2, 2025 The board of directors of the Company is pleased to invite its securities holders to attend the extraordinary shareholders' meeting of the Company, to be held on Wednesday, July 2, 2025 at 2:00 p.m. CET at...

7h / 53m 1 EN
 PRESS RELEASE
Free
NYXH NYXOAH

Invitation à assister à l'assemblée générale extraordinaire des action...

Invitation à assister à l'assemblée générale extraordinaire des actionnaires de la Société qui se tiendra le 2 juillet 2025 INFORMATIONS RÉGLEMENTÉESle 13 juin 2025, 7:00h CET / 1:00h ET NYXOAH SA(Euronext Brussels/Nasdaq: NYXH)Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgique(ci-après la « Société ») Invitation à assister à l'assemblée générale extraordinaire des actionnaires de la Société qui se tiendra le 2 juillet 2025 Le conseil d'administration de la Société a le plaisir d'inviter ses détenteurs de titres à assister à l’assemblée générale extraordinaire des actionnaires de la...

7h / 53m 1 EN
 PRESS RELEASE
Free
NYXH NYXOAH

Publication relating to transparency notifications

Publication relating to transparency notifications                  REGULATED INFORMATION Publication relating to transparency notifications Mont-Saint-Guibert (Belgium), May 30, 2025, 10:30 pm CET / 4:30 pm ET – In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received a transparency notification as detailed below. Vestal Point Capital On May 27, 2025, Nyxoah received a transparency notification from Vestal Point Capital following an acquisition or disposal of voting securities...

May 30, 2025 1 EN
 PRESS RELEASE
Free
NYXH NYXOAH

Publication relative à des notifications de transparence

Publication relative à des notifications de transparence          INFORMATION RÉGLEMENTÉE Publication relative à des notifications de transparence Mont-Saint-Guibert (Belgique), le 30 mai 2025, 22:30h CET / 16:30h ET – Conformément à l'article 14 de la loi du 2 mai 2007 relative à la publicité des participations importantes, Nyxoah SA (Euronext Brussels/Nasdaq : NYXH) annonce qu’elle a reçu une notification de transparence comme détaillée ci-dessous. Vestal Point Capital Le 27 mai 2025, Nyxoah a reçu une notification de transparence de Vestal Point Capital suite à une acquisition ou ce...

May 30, 2025 1 EN
 PRESS RELEASE
Free
NYXH NYXOAH

Nyxoah to Present at the Jefferies Global Healthcare Conference

Nyxoah to Present at the Jefferies Global Healthcare Conference Nyxoah to Present at the Jefferies Global Healthcare Conference Mont-Saint-Guibert, Belgium – May 28, 2025, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA), today announced that the Company will participate in the Jefferies Global Healthcare Conference, which takes place June 3 – 5, 2025 in New York. Olivier Taelman, Nyxoah’s Chief Executive Officer, will deliver a ...

May 28, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch